Related Experiment Video
Updated: Mar 24, 2026
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
Pingdong Cao1, Xiao Jia2, Yuqi Yang1
1Department of Radiation Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, People's Republic of China.
Abstract:
Immune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (AI) has become increasingly applied in cancer treatment, particularly for modeling clinical data and predicting patient prognosis. By integrating multi-omics data such as radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics, AI enables comprehensive biomarker discovery and facilitates prediction of immunotherapy responses and potential toxicities in NSCLC patients. Despite these advancements, challenges such as data standardization, limited interpretability, and technical barriers persist. This review summarizes the application of AI in predicting immunotherapy efficacy for NSCLC patients and discusses the challenges and future directions in the context of precision medicine.
Insights
Artificial intelligence (AI) can predict immunotherapy response in non-small cell lung cancer (NSCLC) by integrating multi-omics data. This approach aids in identifying patients who will benefit from immune checkpoint inhibitors (ICIs) and predicting treatment efficacy.
Area of Science:
- Oncology
- Artificial Intelligence
- Biomarker Discovery
Background:
- Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment, but patient response varies significantly.
- Current biomarkers for predicting ICI efficacy in NSCLC are limited, creating a need for improved predictive tools.
- Artificial intelligence (AI) is emerging as a powerful tool for analyzing complex biological data in cancer research.
Purpose of the Study:
- To review the application of AI in predicting immunotherapy efficacy for NSCLC patients.
- To explore how multi-omics data integration with AI can enhance biomarker discovery for immunotherapy response.
- To discuss the challenges and future directions of AI in precision medicine for NSCLC.
Main Methods:
- Integration of diverse multi-omics data, including radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics.
- Application of AI algorithms for modeling clinical data and predicting patient prognosis and treatment response.
- Review of existing literature on AI-driven prediction of immunotherapy efficacy and toxicities in NSCLC.
Main Results:
- AI models integrating multi-omics data show promise in identifying NSCLC patients likely to respond to immunotherapy.
- AI facilitates comprehensive biomarker discovery, potentially improving the prediction of both efficacy and toxicities of ICIs.
- AI-driven approaches can contribute to personalized treatment strategies in NSCLC.
Conclusions:
- AI holds significant potential to improve the prediction of immunotherapy efficacy in NSCLC, addressing limitations of current biomarkers.
- Further research and development are needed to overcome challenges like data standardization and interpretability for widespread clinical adoption.
- AI-powered precision medicine approaches are crucial for optimizing NSCLC treatment outcomes.
More Related Videos
07:46Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
